. " "@en . . . "Treatment of complicated skin infections caused by gram-positive bacteria like methicillin-susceptible or -resistant Staphylococcus aureus, vancomycin-susceptible Enterococcus faecalis, and Streptococcus pyogenes, Streptococcus agalactiae, or Streptococcus anginosus group. "@en . . . . "Gram-positive Bacteria"@en . . . "372151-71-8"@en . . . . . . ">90% to serum albumin in a concentration independent manner (despite being highly protein bound, antimicrobial activity of telavancin is not affected) "@en . "Terminal elimination half-life = 8 \u00B1 1.5 hours (with normal renal function) "@en . . . "Cl, healthy subjects, 10 mg/kg = 13.9 \u00B1 2.9 mL/h/kg "@en . . . . "# Laohavaleeson S, Kuti JL, Nicolau DP: Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin Investig Drugs. 2007 Mar;16(3):347-57. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17302529 # Rubinstein E, Corey GR, Stryjewski ME, Kanafani ZA: Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia. Expert Opin Pharmacother. 2011 Dec;12(17):2737-50. doi: 10.1517/14656566.2011.633511. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/22077833 # Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagace-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA: New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010 May 7;70(7):859-86. doi: 10.2165/11534440-000000000-00000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20426497 # Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL: Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy. 2010 Feb;30(2):136-43. doi: 10.1592/phco.30.2.136. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20099988"@en . . . "approved"@en . . . . "TD-6424"@en . . . . . . . . . . "Vss, healthy subjects, 10 mg/kg = 0.14 L/kg "@en . . . "Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA is an important pathogen causing hospital-acquired pneumonia (HAP) worldwide) and other gram-positive bacteria. FDA approved on September 11, 2009. "@en . . . . "Telavancin is a bactericidal lipoglycopeptide that is active against a broad range of gram-positive bacteria. Telavancin prevents polymerization of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) and cross-linking of peptidoglycan by binding to D-Ala-D-Ala. As a result, inhibition of bacterial cell wall synthesis occurs. Furthermore, telavancin disrupts membrane potential and cell permeability as a result of the lipophillic side chain moiety. This additional bactericidal mechanism is what sets telavancin apart from vancomycin. "@en . . . "Vibativ"@en . "Telavancin demonstrates linear pharmacokinetics at doses between 1 and 12.5 mg/kg. Furthermore, 24 hours post-infusion of a dose of 7.5 to 15 mg/kg, activity against MRSA and penicillin-resistant Streptococcus pneumonia can still be observed. The trough concentration at this point of time is approximately 10 \u03BCg/mL. Telavancin also has poor bioavailability and must be administered over 30-120 minutes IV. Cmax, healthy subjects, 10 mg/kg = 93.6 \u00B1 14.2 \u03BCg/mL; AUC (0- \u221E), healthy subjects, 10 mg/kg = 747 \u00B1 129 \u03BCg \u00B7 h/mL; AUC (0-24h), healthy subjects, 10 mg/kg = 666\u00B1 107 \u03BCg \u00B7 h/mL; Time to steady state = 3 days;"@en . " "@en . "Urine with >80% as unchanged drug and <20% as hydroxylated metabolites (with dose of 10mg/kg); Feces (<1%) "@en . "Telavancin"@en . . . .